Development and deployment of COVID-19 vaccines for those most vulnerable.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33536277.
- Also identified by DOI 10.1126/scitranslmed.abd1525.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.
Medical subject headings
- COVID-19
- COVID-19 Vaccines
- Disease Susceptibility
- SARS-CoV-2